Graybill Wealth Management’s Carisma Therapeutics CARM Stock Holding History

Graybill Wealth Management’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-500	Closed	-$46K	–	51
2021 Q2	$46K	Buy	+500	New	+$31.9K	0.02%	53

Other funds holding CARM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Graybill Wealth Management's CARM Position: Q3 2021 in Review

Graybill Wealth Management sold out of Carisma Therapeutics (CARM) in Q3 2021, closing a stake of 500 shares — an estimated $46K sold.

Graybill Wealth Management first reported a position in CARM in Q2 2021 and held it in 1 quarter. The position peaked at $46K in Q2 2021. 103 funds tracked by Wall St. Rank hold CARM as of Q3 2021.

Graybill Wealth Management reported no remaining Carisma Therapeutics position as of Q3 2021 after selling out during the quarter.
Graybill Wealth Management sold 500 Carisma Therapeutics shares in Q3 2021, an estimated $46K.
Graybill Wealth Management first reported a position in Carisma Therapeutics in Q2 2021 and held it in 1 quarter.
Graybill Wealth Management's Carisma Therapeutics position peaked at $46K in Q2 2021.
103 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2021.

Based on Graybill Wealth Management's 13F filing for Q3 2021, filed 22 Oct 2021.